For squamous cell carcinoma, patients with Thr/Met genotype at XRCC3 showed a significantly shorter survival time than those with the Thr/Thr genotype (13 months versus 48 months; log-rank test, p < 0.0001) (Figure 1). Here, XRCC3 is linked to squamous cell carcinoma.